Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed By Consolidation Chemotherapy In Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Principal Investigator
Martin Edelman, MD
Status
Terminated
Date Opened To Accrual
November 30 2010
Date Closed to Accrual
August 03 2015
Date of Study Termination
May 20 2022
Disease Site
Lung [LU]
Non-small Cell Lung Cancer
Phase
II
Developmental Therapeutics
No
Primary Objective
Mediastinal nodal clearance following completion of induction chemoradiation +/- panitumumab
Patient Population
Pathologically proven diagnosis Stage IIIA (T1-T3) with a single primary lung parenchymal lesion and N2 positive ipsilateral mediastinal nodes
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Target Accrual
97
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.